medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2021, Number 1

<< Back Next >>

Rev Latin Infect Pediatr 2021; 34 (1)

Diagnosis, stabilization and treatment of SARS-CoV-2-linked pediatric multisystemic inflammatory syndrome (SIM-PedS)

García-Salido A, Antón J, Martínez-Pajares JD, Giralt-García G, Gómez-Cortés B, Tagarro A

Language: Spanish
References: 39
Page: 6-16
PDF size: 317.94 Kb.


ABSTRACT

A new pediatric multisystemic inflammatory syndrome linked to SARS-CoV-2 has been described. This picture presents a variable clinical expressivity and is associated with active or recent SARS-CoV-2 infection. This paper reviews the existing literature by a multidisciplinary group of pediatric specialists. Subsequently, recommendations on stabilization, diagnosis and treatment of this syndrome are made.


REFERENCES

  1. García SA, Antón J, Martínez PJ et al. Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]. An Pediatr (Barc). 2021; 94 (2): 116.e1-116.e11. Spanish. doi: 10.1016/j.anpedi.2020.09.005.

  2. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020. [Accessed June 16, 2020].

  3. Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. 2020. [Accessed 19 June 2020] Available in: https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment.

  4. Abdel-Mannan O, Eyre M, Lobel U et al. Neurologic and radiographic findings associated with COVID-19 infection in children. JAMA Neurol. 2020; 77 (11): 1440-1445.

  5. McCrindle BW, Rowley AH, Newburger JW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 135: e927-e99.

  6. Whittaker E, Bamford A, Kenny J et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020; 324 (3): 259-269.

  7. Weiss SL, Peters MJ, Alhazzani W et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med. 2020; 21: e52-e106.

  8. Ramcharan T, Nolan O, Lai CY et al. Paediatric inflammatory multi-system syndrome-temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr Cardiol. 2020; 12: 1-11.

  9. Belhadjer Z, Meot M, Bajolle F et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020; 142 (5): 429-436.

  10. Verdoni L, Mazza A, Gervasoni A et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet (London, England). 2020; 395: 1771-1778.

  11. Kaushik S, Aydin SI, Derespina KR et al. Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection: a multi-institutional Study from New York City. J Pediatr 2020; 224: 24-29.

  12. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395: 1607-1608.

  13. Toubiana J, Poirault C, Corsia A et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020; 369: m2094.

  14. Wang F, Nie J, Wang H et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of Infectious Diseases. 2020; 221: 1762-1769.

  15. Bordoni V, Sacchi A, Cimini E et al. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19. Clin Infectious Dis. 2020; 71 (16): 2272-2275.

  16. Cabrero-Hernandez M, Garcia-Salido A, Leoz-Gordillo I et al. Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in spain. Pediatr Infect Dis J. 2020; 39 (8): e195-e198.

  17. Henderson LA, Canna SW, Schulert GS et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020; 72: 1059-1063.

  18. Lou B, Li TD, Zheng SF et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J 2020; 56: 2000763.

  19. Tagarro A, Epalza C, Santos M et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2021; 175 (3): 316-317.

  20. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020; 323 (22): 2249-2251.

  21. Feldstein LR, Rose EB, Horwitz SM et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020; 383: 334-346.

  22. Barrios TA, Centeno MF, Rojo SH et al. National consensus on the cardiological treatment and follow-up of Kawasaki disease. Anales de Pediatria. 2018; 89: 188e1-e22.

  23. Davies P, Evans C, Kanthimathinathan HK et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. The Lancet Child & Adolescent Health. 2020; 4 (9): 669-677.

  24. Documento de manejo clínico del paciente pediátrico con infección por SARS-CoV-2 en cuidados intensivos. 2020. [Accesado 30 Junio 2020] Disponible en: https://secip.com/wp-content/uploads/2020/05/Protocolo-de-manejo-cl%C3%ADnico-COVID-19-en-UCI-20200518.pdf.

  25. Verbeek JH, Ijaz S, Mischke C et al. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. The Cochrane Database of Systematic Reviews. 2016; 4: CD011621.

  26. Cinesi GC, Peñuelas RO, Luján TM et al. Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection. Arch Bronconeumol. 2020; 56 (Suppl 2): 11-18.

  27. Pediatric Acute Lung Injury Consensus Conference G. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015; 16: 428-439.

  28. Ramcharan T, Nolan O, Lai CY et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020; 41 (7): 1391-1401.

  29. Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and hyperinflammation in COVID-19. 2020. [Accessed 23 June, 2020] Available in: https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-MIS-C-Hyperinflammation.pdf.

  30. Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020; 2 (6): e358-e367.

  31. Guaraldi G, Meschiari M, Cozzi-Lepri A et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020; 2 (8): e474-e484.

  32. Nozawa T, Imagawa T, Ito S. Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki's disease. N Engl J Med. 2017; 377: 1894-1896.

  33. Bhimraj A, Morgan RL, Shumaker AH et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020; ciaa478.

  34. Sarma P, Kaur H, Kumar H et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. J Med Virol. 2020; 92: 776-785.

  35. Tang W, Cao Z, Han M et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369: m1849.

  36. Cavalcanti AB, Zampieri FG, Rosa RG et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020; 383: e119.

  37. Rosenberg ES, Dufort EM, Udo T et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020; 323 (24): 2493-2502.

  38. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England). 2020; 395: 1569-1578.

  39. Shekar K, Badulak J, Peek G et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J. 2020; 66 (7): 707-721.




2020     |     www.medigraphic.com